Лучшие подкасты про Oncology Times (2024)

1
Artificial Intelligence Tool Predicts Postoperative Radiotherapy Lymphedema 34:36

8d ago34:36

34:36

Artificial intelligence is being harnessed by a team of researchers at Leicester University in the United Kingdom to predict the risk of lymphedema (and potentially other toxicities) from the use of postoperative radiation therapy for breast cancer. The 2024 European Breast Cancer Conference heard the latest news on an artificial intelligence tool …

1
Neoadjuvant Pembrolizumab Improves High-Risk Early Breast Cancer Outcomes 8:47

9d ago8:47

8:47

New data from the Phase III KEYNOTE-756 clinical trial show that adding pembrolizumab immunotherapy to chemotherapy before and after surgery for high-risk breast cancer (which was estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative) resulted in better outcomes for patients regardless of their age or menopaus…

1
Preoperative Partial Breast Irradiation: Marked Benefit in Low-Risk Breast Cancer 9:00

12d ago9:00

9:00

Offering MRI-guided partial breast irradiation before surgery to patients with low-risk breast cancer could become the norm, according to Yasmin Civil, MD, in the Department of Radiation Oncology at the Amsterdam UMC in the Netherlands, who reported 5-year results from the ABLATIVE trial to the 14th European Breast Cancer Conference. The researcher…

1
Adjuvant Atezolizumab: No Survival Benefit in Triple-Negative Breast Cancer 9:35

13d ago9:35

9:35

Adding checkpoint inhibition immunotherapy to adjuvant chemotherapy did not improve survival among patients with triple-negative breast cancers. These findings from a study reported at the 14th European Breast Cancer Conference were presented by Heather McArthur, MD, MPH, Clinical Director of Breast Cancer and Komen Distinguished Chair in Clinical …

1
Gene Test Shows Which Triple-Negative Breast Cancers Do Not Need Pre-Op Pembrolizumab 15:44

28d ago15:44

15:44

About a quarter of all patients with newly diagnosed triple-negative breast cancer will not benefit from neoadjuvant checkpoint inhibitor immunotherapy with an agent such as pembrolizumab—even though it improves outcomes among the remaining majority. At the 14th European Breast Cancer Conference, held in Milan, Italy, Laura van ’t Veer, PhD, Progra…

1
Triple Therapy for Patients With Mutated FLT3 Gene in Acute Myeloid Leukemia 20:15

1M ago20:15

20:15

An early study of patients (Phase I/II) with acute myeloid leukemia found that a new three-drug combination therapy greatly improved outcomes—both in patients with relapsed or refractory disease and as initial therapy. The new research involved adding quizartinib that targets fms-related tyrosine kinase 3 (FLT3) oncogene. Mutations of FLT3 are pres…

1
Important Mantle Cell Lymphoma Findings From the Sympatico Study 13:55

1M ago13:55

13:55

How best to treat patients with relapsed or refractory mantle cell lymphoma has been made clearer by a report from the multinational Phase III Sympatico Study, presented at the 65th ASH Annual Meeting and Exposition held in San Diego. Lead author Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at the University of Texas MD Ander…

1
World’s Largest Prostate Cancer Trial, STAMPEDE, Celebrates 20 Years of Progress 17:44

2M ago17:44

17:44

2024 is the 20th year of clinical studies conducted as part of the STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy) trial, a series of investigational approaches to initial therapy for patients with high-risk prostate cancer. Patient accrual has now ended, but practice-changing data continue to eme…

1
Doublet Inhibitor Therapy Restrains Metastatic EGFR-Mutated NSCLC Progression 16:00

2M ago16:00

16:00

The multicenter RAMOSE randomized clinical trial has found that doublet growth factor tyrosine kinase inhibitor therapy, when compared with standard osimertinib monotherapy, achieved a statistically significant improvement in progression-free survival in patients whose advanced non-small cell lung cancers were driven by mutated epidermal growth fac…

1
Gene-Targeted Agent Brings Clinical Benefit in R/R Acute Leukemias 24:23

2M ago24:23

24:23

A new targeted drug, revumenib, was found to increase response rates and survival in patients whose previously treated acute leukemias relapsed or were refractory to treatment. A Phase II clinical study found revumenib met its primary endpoint and was stopped early because of a high patient response rate and clinical efficacy. Revumenib acts on the…

1
INTERLACE Study Boosts Cervical Cancer Survival 18:14

2M ago18:14

18:14

A marked improvement in the outlook for patients with locally advanced cervical cancer has been achieved thanks to a neoadjuvant regimen using standard anti-cancer drugs added to usual therapy. At the ESMO Congress 2023 held in Madrid, Spain, Mary McCormack, PhD, MBBS, FRCR, Consultant Clinical Oncologist at University College London Hospitals, rep…

1
RET Fusion-Targeted Drug Doubles Progression-Free Survival in NSCLC Patients 18:43

2M ago18:43

18:43

Patients whose advanced non-small cell lung cancers harbor the RET gene fusion should receive initial treatment with the RET-targeted agent selpercatinib rather than chemotherapy or chemotherapy combined with immunotherapy. This clear message comes from the randomized Phase III LIBRETTO-431 study reported at ESMO Congress 2023 by Herbert Ho Fung Lo…

1
Afatinib Recommended for Non-Small Cell Lung Cancer With Uncommon EGFR Mutations 8:33

2M ago8:33

8:33

The preferred first-line treatment for patients with uncommon sensitizing mutations in tumor epidermal growth factor receptor (EGFR) should now be the tyrosine kinase inhibitor (TKI) afatinib, rather than osimertinib, according to Japanese researchers reporting the ACHILLES trial results at the ESMO Congress 2023 held in Madrid. OncTimesTalk corres…

1
Adjuvant Radiotherapy No Benefit After Radical Prostatectomy 15:24

2M ago15:24

15:24

Patients with high-risk prostate cancer who have been treated with radical prostatectomy gain no additional advantage and face extra toxicity if they choose to have adjuvant radiotherapy. That’s according to the findings of the randomized RADICALS study, reported at the ESMO Congress 2023. These results support the use of early salvage radiotherapy…

1
Collagen-Bound Interleukin 12 Converts “Cold” Tumors Into “Hot” Ones 14:51

2M ago14:51

14:51

Although immunotherapies for patients with solid tumors such as melanoma can be dramatically successful, the majority of patients are resistant and require alternative treatments. While the cytokine interleukin-12 is well known for potentiating the effect of immunotherapies, such as checkpoint blockade, it couldn’t be used because of toxicity. At t…

1
Allogeneic Transplant for AML: Only in Patients Negative for Molecular Minimum Residual Disease 15:43

3M ago15:43

15:43

The process of identifying which patients with acute myeloid leukemia (AML) can benefit from allogeneic stem cell transplantation in first complete remission (CR1) has taken a step forward thanks to analysis of the UK NCRI AML17 and AML19 studies, reported at the 65th ASH Annual Meeting and Exposition. Patients who achieved molecular residual disea…

1
Antibody-Drug Conjugate Brings Success in High-Risk R/R Follicular Lymphoma 22:11

3M ago22:11

22:11

With no standard-of-care treatment for patients with high-risk relapsed/refractory follicular lymphoma, promising remissions have been observed in a Phase II study reported at the 65th ASH Annual Meeting and Exposition. The antibody-drug conjugate loncastuximab tesirine in combination with rituximab brought a very high complete metabolic response r…

1
Pirtobrutinib After Covalent BTK Inhibitor - Double Refractory CLL 12:16

3M ago12:16

12:16

Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have poor outcomes after the failure of covalent Bruton's tyrosine kinase (BTK) inhibitor treatment, and new therapeutic options are needed. Pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor, was designed to re-establish BTK inhibition.…

1
Relapsed or Refractory CLL - With Sameer A. Parikh, MBBS, and Alessandra Ferrajoli, MD 12:32

3M ago12:32

12:32

In a multinational, Phase III, head-to-head trial, ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater specificity, as treatment for relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). In prespecified interim analyses, zanubrutinib was superio…

1
CLL Frontline Treatment - With Sameer A. Parikh, MBBS, & Alessandra Ferrajoli, MD 14:40

3M ago14:40

14:40

Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia (CLL) have been lacking.

1
Sabestomig in Non-Small Cell Lung Cancer: Bi-Specific Antibody Safe and Active 11:10

5M ago11:10

11:10

Patients with non-small cell lung cancer who have failed initial immunotherapy therapy with anti-programmed cell death ligand-1 (PDL-1) checkpoint inhibitors, have responded to a new “bispecific” antibody that targets both the programmed cell death-1 (PD-1) antibody and also the T-cell immunoglobulin and mucin domain 3 (TIM-3) molecule. Benjamin Be…

1
Radicals Study Finds Adjuvant Radiotherapy No Benefit After Radical Prostatectomy 15:23

5M ago15:23

15:23

Patients with high-risk prostate cancer who have been treated with radical prostatectomy gain no additional advantage and face extra toxicity if they choose to have adjuvant radiotherapy. That’s according to the findings of the randomized RADICALS study, reported at the 2023 annual congress of the European Society for Medical Oncology (ESMO) held i…

1
Two Drug Combination Benefits Patients with nRAS-Mutated Melanoma Refractory to Checkpoint Inhibition 13:38

5M ago13:38

13:38

Research presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics found that a combination of two drugs targeting the nRAS mutation had clinical activity in patients with checkpoint-inhibitor refractory melanoma and had potential for treating other solid tumors with mutated nRAS as their oncogenic d…

1
Collagen-Bound Interleukin 12 Converts “Cold” Tumors into “Hot” Ones 14:50

5M ago14:50

14:50

Although immunotherapies for patients with solid tumors such as melanoma can be dramatically successful, the majority of patients are resistant and require alternative treatments. While the cytokine interleukin 12 is well known for potentiating the effect of immunotherapies, such as checkpoint blockade, it could not be used because of toxicity. At …

1
Double TKI Therapy Improves Responses in MET Amplification-Driven EGFR-Mutant Non-Small Cell Lung Cancer 15:22

5M ago15:22

15:22

Among patients with non-small cell lung cancers driven by mutations in the epidermal growth factor receptor (EGFR), those with MET-amplification can now be selected for therapy with two tyrosine kinase inhibitor drugs, not just standard osimertinib. That’s according to conclusions from the INSIGHT 2 study reported at the AACR-NCI-EORTC internationa…

1
CLIC Protein Inhibition Key to Metformin’s Anti-Neoplastic Properties 24:17

5M ago24:17

24:17

The Chloride Intracellular Channel 1 (CLIC1) protein appears to hold the key to understanding the anti-proliferative action of metformin, according to laboratory evidence discussed at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held in October 2023, in Boston. At the conference, Michele M. Mazzanti, PhD,…

1
Adjuvant ATR Inhibition Prolonged Life in Patients with Relapsed Small Cell Lung Cancer 18:59

5M ago18:59

18:59

Dr. Takahashi talks with OncTimes Talk’s Peter Goodwin about the Phase 2 study he presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 11 - 15, 2023. Dr. Takahashi reported an improvement in median overall survival among patients with relapsed small cell lung cancer who had the ATR inhibitor…

1
Mitophagy Discovered as Potential Reason for AML’s Resistance to Venetoclax 15:20

5M ago15:20

15:20

Acute myeloid leukemia (AML) is notoriously difficult to treat. Only 28 percent of patients survive beyond 5 years after diagnosis. Mitophagy, a process in which damaged mitochondria are eliminated to prevent the transmission of death signals, has been identified as a key mechanism that allows leukemia cells to resist the effects of the widely pres…

1
Unintentional Bias of Breast Cancer Randomized Clinical Trial Interpretations Through Discontinuation Imbalance 11:54

8M ago11:54

11:54

Some of the big randomized clinical trials could lead to unintentional bias because of an imbalance of assigned treatment discontinuations between experimental and control arms, according to ASCO poster author Faris Tamimi, MD, at the University Health Network Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre. OncTimesT…

1
Trastuzumab Deruxtecan Benefits Patients with HER2-Low Metastatic Breast Cancer Irrespective of ER Expression 11:43

8M ago11:43

11:43

Although T-DXd had already been licensed for use in all categories of HER2 positivity, including patients with so-called HER2-low tumors (defined as having immunohistochemical score of 1+ or 2+ with non-amplified in-situ hybridization), doubts have remained about the effectiveness of this antibody drug conjugate in the subset of such patients who a…

1
Artificial Intelligence Model Predicts Overall Survival in Patients with Metastatic Breast Cancer 9:17

8M ago9:17

9:17

A mathematical study of real-world data from 27,855 women whose breast cancer was diagnosed between 2008 and 2020 has shown that a machine-learning artificial intelligence algorithm was able to predict mortality and could become a key weapon in the clinician’s armory when selecting therapies on the basis of predicted survival. Initial findings and …

1
Axillary Dissection in Older Women With Clinically Node-Negative Breast Cancer 9:17

9M ago9:17

9:17

Caution was expressed at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting about potential adverse effects from one form of breast cancer treatment de-escalation. A poster warns about risks from omitting axillary sentinel node surgery in older women. In this edition of OncTimesTalk correspondent Peter Goodwin hears about axillary…

1
Variability of Biological Parameters Between Tumor Biopsy & Surgical Samples in Breast Cancer Patients 8:16

9M ago8:16

8:16

A real-world study reported at the ESMO Breast Cancer 2023 Annual Congress identified a risk for inappropriate therapeutic decision-making resulting from an alarmingly high rate of false-negative tests coming from biopsy specimens looking for biological parameters such as PR and HER2. Study researchers at the University of Catania suggested tumor h…

1
Full Compliance With Adjuvant Endocrine Therapy Brings 15 Percent Superior Survival in Patients With Breast Cancer 3:42

9M ago3:42

3:42

Patients with breast cancer who complied fully with their adjuvant endocrine medication lived 15 percent longer than those who skipped doses, according to a huge real-world study coordinated from Tübingen University, in Baden-Württemberg, Germany, reported at the 2023 ASCO Annual Meeting. OncTimesTalk correspondent Peter Goodwin discusses the findi…

1
Being Obese & Overweight Reduces Efficacy of Extended Endocrine Therapy in HR+ Breast Cancer 14:17

9M ago14:17

14:17

Being overweight or obese can reduce the benefit of extending adjuvant breast cancer hormone therapy in women younger than 60 years, according to research from the DATA trial discussed at the European Society for Medical Oncology (ESMO) Breast Cancer 2023 Congress. Senna W.M. Lammers, MD, from Maastricht University Medical Centre in The Netherlands…

1
ASCO 2023: Neoadjuvant Pembrolizumab Brought Big Benefit in Early-Stage Non-Small Cell Lung Cancer with Heather A. Wakelee, MD, FASCO 11:05

10M ago11:05

11:05

Non-small cell lung cancer was one of the big topics at the 2023 ASCO Annual Meeting where Heather Wakelee, MD, FASCO, Professor of Medicine and Chief of the Division of Oncology at Stanford University in California, was overheard reminding a junior cancer doctor that the only adjuvant therapy for lung cancer had been chemotherapy just a couple of …

1
ASCO 2023: How AI Can Help Physicians Communicate with Dying Patients Better & Also Reduce Costs 7:14

10M ago7:14

7:14

End-of-life care for patients with cancer could be significantly improved while simultaneously reducing cost according to the findings of a study from the University of Pennsylvania. Ravi Parikh, MD, MPH, talks with OncTimesTalk correspondent Peter Goodwin about his findings on the value of harnessing AI to help doctors have serious illness convers…

1
Targeted Adjuvant Therapy in Non-Small Cell Lung Cancer with Roy Herbst, MD PhD 5:30

10M ago5:30

5:30

Roy Herbst, MD PhD, Deputy Director of the Yale Cancer Center at Yale School of Medicine, talks with OncTimesTalk correspondent Peter Goodwin about his group’s findings from the international Phase III ADAURA clinical trial looking at adjuvant therapy with the anti EGFR-mutant drug osimertinib in patients with completely resected stage one B to thr…

1
Targeted Adjuvant Therapy in Non-Small Cell Lung Cancer with Roy Herbst, MD PhD 11:04

10M ago11:04

11:04

Roy Herbst, MD PhD, Deputy Director of the Yale Cancer Center at Yale School of Medicine, talks with OncTimesTalk correspondent Peter Goodwin about his group’s findings from the international Phase III ADAURA clinical trial looking at adjuvant therapy with the anti EGFR-mutant drug osimertinib in patients with completely resected stage one B to thr…

1
Emerging Cancer Treatments for Esophageal Cancer with Brian Henick, MD 24:46

12M ago24:46

24:46

Progress in esophageal cancer is forging ahead at Columbia University in New York. Brian Henick, MD, is a medical oncologist specializing in the care of patients with malignancies of the aerodigestive tract. As Associate Director of Experimental Therapeutics and Director of Translational Research in Aerodigestive Cancers in Medical Oncology, Henick…

1
Meet the New Oncology Times Editorial Board Chair: Stephanie L. Graff, MD, FACP 15:05

1y ago15:05

15:05

Today we are introducing the new Oncology Times Editorial Board Chair: Stephanie L. Graff, MD, FACP. In her new role, Graff will help Oncology Times continue to provide essential clinical news and analysis for the cancer care community.Graff is Director of Breast Oncology at Lifespan Cancer Institute and Assistant Professor of Medicine at Brown Uni…

1
Ravi B. Parikh, MD, on How Machine Learning-Triggered Reminders Can Improve End-of-Life Care for Cancer Patients 21:05

1y ago21:05

21:05

When cancer advances to an incurable stage, some patients may prioritize treatment that will extend their life as long as possible, and others may prefer a care plan that’s designed to minimize pain. Talking to patients about their prognosis and values can help clinicians develop care plans that are better aligned to each patient’s goals. However, …

1
Deanna Gerber, MD, on Navigating Cervical Cancer Screening 13:02

1y ago13:02

13:02

Despite increased screening and HPV vaccines, cervical cancer remains the fourth-leading cause of cancer death among women worldwide. Screening guidelines are constantly scrutinized and reassessed. The most current U.S. Preventative Services Task Force (USPSTF) guidelines recommend screening for cervical cancer every 3 years with cervical cytology …

1
January Research Review: Promising Results in HemOnc Clinical Trials 43:58

1y ago43:58

43:58

This episode is Research Review, a quarterly review of the research you may have missed. Today, we are covering the American Society of Hematology Annual Meeting highlights. First Up, results from the ECOG-ACRIN E1910 Randomized Phase III clinical trial showed that blinatumomab improved overall survival in newly diagnosed adult patients with b-line…

1
Unraveling a Complex Disease: Gary K. Schwartz, MD, on Sarcoma Research Highlights, Targeted Agents & Future Directions 30:06

1+ y ago30:06

30:06

Sarcoma represents an incredibly rare group of cancers comprised of 50 histologic subtypes, with approximately 13,000 new diagnoses per year. Each histologic type exhibits a unique biologic behavior, and, as such, prognosis and optimal treatment strategies vary. Sarcoma can appear anywhere in the body, and local invasion of nearby organs may make s…

1
ASH 2022: David Sallman, MD, Discusses Positive Phase I Dose Escalation Data for PRGN-3006 UltraCAR-T in AML Patients 17:52

1+ y ago17:52

17:52

A study using chimeric antigen receptor (CAR)-T cells has proven to be safe for treating patients with relapsed or refractory acute myeloid leukemia (AML). The agent known as PRGN-3006 also brought remissions among patients who had chemotherapy for lymphodepletion prior to their CAR-T cell procedure (Abstract 4633). After the lead author of the new…

1
Anil K. Rustgi, MD, on the Current State of Colorectal Cancer Screening 24:47

1+ y ago24:47

24:47

Colorectal cancer is the third most diagnosed cancer and the second leading cause of cancer deaths worldwide. The current gold standard for screening, the colonoscopy, reduces cancer deaths by 67 percent, according to a 2018 study from Kaiser Permanente. So, we know screening is effective. However, obstacles remain. Colonoscopies are invasive and c…

1
Small Bytes: Phase I Study Finds Pan-AKT Inhibitor Ipatasertib Safe & Effective, Featuring Carolyn McCourt, MD 10:51

1+ y ago10:51

10:51

BARCELONA, Spain—Patients with solid tumors expressing mutated AKT oncogenes responded to therapy with a pan-AKT inhibitor—the investigational drug ipatasertib—in a Phase I study reported at the 2022 EORTC—NCI—AACR symposium on Molecular Targets and Cancer Therapeutics. Nearly a quarter of the patients treated with the AKT blocker had their tumors …

1
Small Bytes: How ctDNA Liquid Biopsies Can Detect Myeloid Malignancies & Occult Tumors 11:25

1+ y ago11:25

11:25

BARCELONA, Spain—Liquid biopsies are increasingly used to identify cancer progression and could also provide molecular evidence of higher risk for hematologic malignancies and solid tumors, according to findings from a study of circulating tumor DNA reported at the European Organization for Research and Treatment of Cancer—National Cancer Institute…

1
Dr. Lisa Newman on Eliminating Racial Disparities in Breast Cancer 25:46

1+ y ago25:46

25:46

In oncology today, there is an urgent need to better understand the implications of racial bias and disparities on the health outcomes of patients. Although breast cancer mortality rates decreased by 43 percent from 1989 to 2020, Black women remain more likely to die from breast cancer compared with White women, according to the 2022 American Cance…

Подкасты, которые стоит послушать

Подкасты на тему Oncology Times

Подкасты, которые стоит послушать

Краткое руководство